Headlines about SenesTech (NASDAQ:SNES) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SenesTech earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news coverage about the company an impact score of 48.0904928674568 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised SenesTech from a “sell” rating to a “hold” rating in a research report on Wednesday, June 20th. ValuEngine raised SenesTech from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd.

NASDAQ SNES traded down $0.02 on Friday, reaching $0.82. 120,833 shares of the stock traded hands, compared to its average volume of 442,544. The company has a quick ratio of 4.07, a current ratio of 5.05 and a debt-to-equity ratio of 0.05. The firm has a market cap of $19.68 million, a PE ratio of -0.73 and a beta of 1.95. SenesTech has a 12 month low of $0.30 and a 12 month high of $3.87.

SenesTech (NASDAQ:SNES) last issued its earnings results on Monday, August 13th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.12). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.40 million. SenesTech had a negative net margin of 13,362.22% and a negative return on equity of 214.75%. research analysts expect that SenesTech will post -0.61 earnings per share for the current year.

About SenesTech

SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.

Further Reading: How Do I Invest in Dividend Stocks

Insider Buying and Selling by Quarter for SenesTech (NASDAQ:SNES)

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.